Monday, 16 July 2018 - 13:42
  • it
  • de
  • en
  • fr

Astellas Pharma

Astellas acquires Mitobridge, worth $450m

Japan-based Astellas has acquired Mitobridge for $165.5m. Mitobridge is a biotech company headquartered in Cambridge (Massachusetts), focusing on the development of small molecules that target mitochondrial function. The deal includes an upfront $225m payment, plus an additional $225m payment based…

Astellas Pharma to close down Agensys center with 220 employees

Astellas Pharma, Japan-based pharmaceutical group focusing on urology, oncology, immunology and nephrology, yesterday announced on a press release it plans to wind down the Santa Monica, California-based Agensys center, focusing on ADC (Antibody-Drug Conjugate). The facility has 220 employees, whose…

Astellas pursuing M&A again: Ogeda acquired for €800m

Japan-based Astellas Pharma announced today before trading opened in Tokyo that it has acquired Belgium-based Ogeda SA for €800m. Ogeda develops novel drugs which bind to GPCR receptors. Its lead investigational product is fezolinetant, a non-hormonal therapy which has delivered…

Record year for German biotechs

2016 has brought highly satisfying results to Germany-based biotechs: Morphosys is obtaining very good clinical results. Aicuris (Wuppertal) has convinced many investors with highly positive data on novel antivirals. Ganymed has obtained results so satisfactory from its intestine cancer treatment…